The objective of the current research was to explore the potential prognostic value of readily available clinical and pathologic variables in bladder cancer. The novel association found between cholesterol levels and prognosis may provide the rationale for exploring novel treatments. Patients included had histologically confirmed urothelial bladder cancer and were treated with at least 3 cycles of cisplatin-based neoadjuvant chemotherapy before radical cystectomy with lymphadenectomy. A total of 245 patients at low, intermediate and high risk, presenting with 0-1, 2 or 3-4 risk factors, including positive lymph nodes, Hb <12.8, NLR >= 2.7 and cholesterol levels >= 199, were included. Five-year cancer-specific survival rate was 0.67, 0.78 and 0.94 at high, intermediate and low risk, respectively. Total cholesterol levels at the time of cystectomy may represent a commonly assessable prognostic factor and may be incorporated in a clinically meaningful risk-group classification model.This present study assessed a large group of patients with urothelial bladder cancer treated with chemotherapy followed by radical cystectomy, to capture the predictive power of commonly collected clinical, pathological and biochemical factors. The design of the study highlighted that higher cholesterol levels at the time of cystectomy were associated with shorter cancer-specific survival. This finding suggests that high blood-cholesterol levels truly have a negative influence on surviving cancer. In conclusion, total cholesterol levels at the time of cystectomy may represent a commonly assessable prognostic factor and could be incorporated into a clinically meaningful and valuable risk-group classification model.

A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapy / M. Ferro, G. Lucarelli, O. de Cobelli, P. Dolce, D. Terracciano, G. Musi, A. Porreca, G.M. Busetto, F. Del Giudice, F. Soria, P. Gontero, F. Cantiello, R. Damiano, F. Crocerossa, A.R. Abu Farhan, R. Autorino, M.D. Vartolomei, M. Marchioni, A. Mari, A. Minervini, N. Longo, G. Celentano, F. Chiancone, S. Perdonà, P. Del Prete, P. Ditonno, M. Battaglia, S. Zamboni, A. Antonelli, F. Greco, G.I. Russo, R. Hurle, N. Crisan, M. Manfredi, F. Porpiglia, D. Ribera, P. De Placido, S. Facchini, L. Scafuri, A. Verde, G. Di Lorenzo, V. Cosimato, A. Luciano, V.F. Caputo, F. Crocetto, C. Buonerba. - In: FUTURE ONCOLOGY. - ISSN 1744-8301. - 17:30(2021 Oct), pp. 3987-3994. [10.2217/fon-2020-1298]

A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapy

O. de Cobelli;G. Musi;G. Celentano;A. Antonelli;
2021

Abstract

The objective of the current research was to explore the potential prognostic value of readily available clinical and pathologic variables in bladder cancer. The novel association found between cholesterol levels and prognosis may provide the rationale for exploring novel treatments. Patients included had histologically confirmed urothelial bladder cancer and were treated with at least 3 cycles of cisplatin-based neoadjuvant chemotherapy before radical cystectomy with lymphadenectomy. A total of 245 patients at low, intermediate and high risk, presenting with 0-1, 2 or 3-4 risk factors, including positive lymph nodes, Hb <12.8, NLR >= 2.7 and cholesterol levels >= 199, were included. Five-year cancer-specific survival rate was 0.67, 0.78 and 0.94 at high, intermediate and low risk, respectively. Total cholesterol levels at the time of cystectomy may represent a commonly assessable prognostic factor and may be incorporated in a clinically meaningful risk-group classification model.This present study assessed a large group of patients with urothelial bladder cancer treated with chemotherapy followed by radical cystectomy, to capture the predictive power of commonly collected clinical, pathological and biochemical factors. The design of the study highlighted that higher cholesterol levels at the time of cystectomy were associated with shorter cancer-specific survival. This finding suggests that high blood-cholesterol levels truly have a negative influence on surviving cancer. In conclusion, total cholesterol levels at the time of cystectomy may represent a commonly assessable prognostic factor and could be incorporated into a clinically meaningful and valuable risk-group classification model.
bladder cancer; neoadjuvant chemotherapy; radical cystectomy;
Settore MED/24 - Urologia
19-lug-2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
future_oncol_2021_v17_p3987_ferro.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.5 MB
Formato Adobe PDF
1.5 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/951976
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact